Innocoll Biotherapeutics recently opened its new U.S. headquarters at 210 Carnegie Center in West Windsor during a recent ceremony with Mayor Hemant Marathe, CEO Louis Pascarella and Drew Persson of Avison Young’s New Jersey office. — Courtesy: Avison Young
By Tina Traster
A pharmaceutical company has opened its new U.S. headquarters in West Windsor after signing a long-term, 10,000-square-foot lease, according to a brokerage team with Avison Young.
Innocoll Biotherapeutics unveiled the space at 210 Carnegie Center during a recent ribbon-cutting ceremony with West Windsor Mayor Hemant Marathe, CEO Louis Pascarella and Drew Persson of Avison Young’s New Jersey office. The company relocated its U.S. operations to New Jersey from its previous space at 3803 West Chester Pike in Newton Square, Pennsylvania.
Persson, a principal based in Avison Young’s New Jersey office, represented Innocoll in the relocation and expansion. CBRE represented the sub-landlord, Labcorp, while landlord Boston Properties was represented in house.
“Innocoll’s relocation and expansion not only speaks to the company’s continued growth and the biopharmaceutical industry’s need for its revolutionary products, but to the value of New Jersey’s local talent pool to office occupiers,” Persson said.
Innocoll is a biotherapeutics pharmaceutical company focused on the development and commercialization of pharmaceutical technologies designed to address health care challenges via its proprietary collagen-based technology platform, according to a news release. The company’s current late-stage product pipeline is focused on addressing patients’ needs for postsurgical pain management to combat the opioid epidemic and reduce recovery time.
“Avison Young understood the type of property and location that would align with our expansion plans as we continue to grow and pursue new business opportunities,” Pascarella said. “Relocating to Princeton provides us with access to a strong life sciences talent pool in an amenity-rich property.”
